

# Genitourinary Cancers in the Era of Precision Medicine

[www.eeoogek-congresses.gr](http://www.eeoogek-congresses.gr)

**3-4**  
Δεκεμβρίου  
**2021**

Ξενοδοχείο  
Divani Caravel  
Αθήνα



Οργάνωση  
Ελληνική  
Ερευνητική Ομάδα  
Ουρογεννητικού  
Καρκίνου (ΕΕΟΟΓΕΚ)

ο ρόλος της ακτινοθεραπείας στον  
ολιγομεταστατικό καρκίνο προστάτη

Ιωάννης Γεωργακόπουλος  
Επίκουρος Καθηγητής  
Ακτινοθεραπευτικής Ογκολογίας Ε.Κ.Π.Α.

# outline

- general facts oligometastatic disease
- oligometastastasis in prostate cancer

# oligometastatic disease general facts

# definitions

## oligometastatic disease

- Hellman S and Weichselbaum RR (*JCO* 1995, *Nat Rev Clin Oncol* 2011)
  - pts with a limited number of clinically detectable metastatic tumours
  - hypothetical transitional state between localized and widespread systemic disease
  - local control of oligometastasis could delay (or avoid) the systemic spreading?
- oligometastasis
  - metastatic state with limited burden
  - 1 to 5 metastasis

“subset of pts with limited volume metastatic disease who not only have an improved prognosis, but in whom treatment of the oligometastatic site(s) impacts survival”

Hellman and Weichselbaum, *JCO* 1995

Weichselbaum and Hellman, *Nat Rev Clin Oncol* 2011

# definitions

## oligometastatic disease

oligometastases

```
graph TD; A[oligometastases] --- B[synchronous]; A --- C[metachronous]
```

synchronous

metachronous

oligopersistence

oligorecurrence

```
graph TD; A[oligorecurrence] --- B[regional]; A --- C[systemic]
```

regional

systemic

oligoprogression

# definitions

## **synchronous oligometastatic disease**

de-novo presentation of oligo-metastases

## **metachronous oligometastatic disease**

after period of initial disease-free interval, new presentation of oligo-metastases


## **oligoprogressive disease**

majority of metastatic disease controlled by systemic treatment but a few “resistant” clones progress

## **oligorecurrence**

limited metastases in the presence of a treated (controlled) primary lesion

# ESTRO/EORTC consensus recommendation



# questions about oligometastatic disease

## true or false oligometastatic disease

### **“true” oligometastatic disease**

relative steady-state and slowly growing disease. In this case, local control of oligometastases makes sense

### **“false” oligometastatic disease**

in this case the occult systemic spreading is ongoing, but a limited number of metastatic sites are detectable; in this case, systemic treatment is needed



# questions about oligometastatic disease

## tailored definition & treatment strategy

- number of met detected by the ideal method?
- taken into account the natural history of the disease?
- taken into account the available method for treating oligometastasis?
- taken into account previously done treatment?
- including the “aim” of local treatment of oligometastasis

**cure the patient?**

**avoid or delay the starting of other lines of systemic treatment?**

# questions about oligometastatic disease in prostate cancer

## clinical scenarios?

- oligometastatic castration sensitive disease at diagnosis with untreated primary
- oligometastatic castration sensitive disease after primary treatment (primary controlled)
- oligometastatic castration resistant disease at its first occurrence
- oligoprogressive castration resistant disease in treatment with Androgen Receptor Target Agent (ARTA)